BRPI0907196A2 - Método para inibir ativação do complexo de receptor heteromérico il-17ra-il-17rb - Google Patents
Método para inibir ativação do complexo de receptor heteromérico il-17ra-il-17rbInfo
- Publication number
- BRPI0907196A2 BRPI0907196A2 BRPI0907196-2A BRPI0907196A BRPI0907196A2 BR PI0907196 A2 BRPI0907196 A2 BR PI0907196A2 BR PI0907196 A BRPI0907196 A BR PI0907196A BR PI0907196 A2 BRPI0907196 A2 BR PI0907196A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor complex
- inhibit activation
- heteromeric receptor
- heteromeric
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6653808P | 2008-02-21 | 2008-02-21 | |
| US61/066,538 | 2008-02-21 | ||
| US14590109P | 2009-01-20 | 2009-01-20 | |
| US61/145,901 | 2009-01-20 | ||
| PCT/US2009/001085 WO2009136976A2 (en) | 2008-02-21 | 2009-02-20 | Il-17ra-il-17rb antagonists and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0907196A2 true BRPI0907196A2 (pt) | 2015-07-14 |
| BRPI0907196B1 BRPI0907196B1 (pt) | 2021-05-25 |
Family
ID=41265206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907196-2A BRPI0907196B1 (pt) | 2008-02-21 | 2009-02-20 | Uso de um antagonista de il-17ra-il-17rb |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20110052600A1 (pt) |
| EP (1) | EP2250200A2 (pt) |
| JP (3) | JP2011514335A (pt) |
| KR (1) | KR101240904B1 (pt) |
| CN (2) | CN104151428B (pt) |
| AU (2) | AU2009244878B2 (pt) |
| BR (1) | BRPI0907196B1 (pt) |
| CA (1) | CA2715503C (pt) |
| MX (1) | MX2010009100A (pt) |
| MY (1) | MY184345A (pt) |
| WO (1) | WO2009136976A2 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| GB0905972D0 (en) * | 2009-04-06 | 2009-05-20 | Medical Res Council | Antibodies against IL-17BR |
| EA031209B9 (ru) | 2010-01-15 | 2021-11-19 | Кирин-Эмджен, Инк. | Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения |
| CA2795043C (en) | 2010-03-30 | 2019-04-23 | Janssen Biotech, Inc. | Humanized il-25 antibodies |
| CN103339145A (zh) * | 2010-09-22 | 2013-10-02 | 安姆根有限公司 | 运载体免疫球蛋白及其用途 |
| CN102188707B (zh) * | 2011-02-25 | 2015-08-05 | 中国医学科学院基础医学研究所 | Il-17抑制剂在制备治疗流感的药物中的用途 |
| WO2013016220A1 (en) * | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| WO2013186236A1 (en) | 2012-06-12 | 2013-12-19 | Orega Biotech | Antagonists of il-17 isoforms and their uses |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| CA2910766C (en) | 2013-04-30 | 2020-12-15 | Otitopic Inc. | Dry powder formulations and methods of use |
| US9858304B2 (en) * | 2014-04-15 | 2018-01-02 | Raytheon Company | Computing cross-correlations for sparse data |
| JP2017537891A (ja) * | 2014-10-31 | 2017-12-21 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−１７ａ及びｉｌ−１７ｆ交差反応性抗体変異体、ならびにそれらを含む組成物、それらを作製する方法、及び使用する方法 |
| WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
| CN106729634A (zh) * | 2017-01-05 | 2017-05-31 | 中国科学院微生物研究所 | 白介素17在抵御流感病毒侵染中的应用 |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| CA3076353A1 (en) | 2017-09-22 | 2019-03-28 | Otitopic Inc. | Dry powder compositions with magnesium stearate |
| US20240124528A1 (en) * | 2020-12-14 | 2024-04-18 | Academia Sinica | Antagonist of interleukin-17b receptor (il-17rb) and use thereof |
| TWI811957B (zh) * | 2021-01-14 | 2023-08-11 | 中央研究院 | 重組多肽，包含該重組多肽的複合物，以及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4373495B2 (ja) * | 1995-03-23 | 2009-11-25 | イミュネックス・コーポレーション | Ｉｌ−１７受容体 |
| US6680057B1 (en) * | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
| AU9482498A (en) * | 1997-09-17 | 1999-04-05 | Human Genome Sciences, Inc. | Interleukin-17 receptor-like protein |
| US6849719B2 (en) * | 1997-09-17 | 2005-02-01 | Human Genome Sciences, Inc. | Antibody to an IL-17 receptor like protein |
| US6482923B1 (en) * | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
| US20030180255A1 (en) * | 2000-08-24 | 2003-09-25 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| JP2004517918A (ja) * | 2000-10-18 | 2004-06-17 | イミュネックス・コーポレーション | Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法 |
| CA2596986A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Use of il-17f in diagnosis and therapy of airway inflammation |
| EP2322219A3 (en) * | 2005-09-01 | 2013-06-05 | Merck Sharp & Dohme Corp. | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease |
| US7833527B2 (en) * | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP2170958A1 (en) * | 2007-06-13 | 2010-04-07 | Amgen Inc. | Il-17 heteromeric receptor complex |
| WO2009069355A1 (ja) * | 2007-11-28 | 2009-06-04 | Riken | Ｉｌ－１７ｒｂ陽性ｎｋｔ細胞を用いたアレルギー性気道炎症及び／又は気道過敏症の治療薬のスクリーニング方法 |
-
2009
- 2009-02-20 CN CN201410242489.3A patent/CN104151428B/zh active Active
- 2009-02-20 MX MX2010009100A patent/MX2010009100A/es active IP Right Grant
- 2009-02-20 WO PCT/US2009/001085 patent/WO2009136976A2/en not_active Ceased
- 2009-02-20 CA CA2715503A patent/CA2715503C/en active Active
- 2009-02-20 EP EP09742963A patent/EP2250200A2/en not_active Withdrawn
- 2009-02-20 AU AU2009244878A patent/AU2009244878B2/en active Active
- 2009-02-20 US US12/918,449 patent/US20110052600A1/en not_active Abandoned
- 2009-02-20 KR KR1020107021168A patent/KR101240904B1/ko active Active
- 2009-02-20 CN CN200980115731.8A patent/CN102037017B/zh active Active
- 2009-02-20 BR BRPI0907196-2A patent/BRPI0907196B1/pt active IP Right Grant
- 2009-02-20 MY MYPI2010003877A patent/MY184345A/en unknown
- 2009-02-20 JP JP2010547641A patent/JP2011514335A/ja active Pending
-
2013
- 2013-05-16 AU AU2013205944A patent/AU2013205944A1/en not_active Abandoned
-
2014
- 2014-02-13 JP JP2014025504A patent/JP2014122231A/ja not_active Withdrawn
- 2014-04-28 US US14/263,534 patent/US20140322238A1/en not_active Abandoned
- 2014-06-04 JP JP2014115952A patent/JP5647748B2/ja active Active
-
2016
- 2016-01-12 US US14/994,108 patent/US20160208004A1/en not_active Abandoned
- 2016-11-02 US US15/341,870 patent/US20170114140A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2715503C (en) | 2016-08-09 |
| HK1203980A1 (en) | 2015-11-06 |
| AU2009244878A2 (en) | 2010-10-14 |
| JP2014185162A (ja) | 2014-10-02 |
| AU2009244878A1 (en) | 2009-11-12 |
| WO2009136976A3 (en) | 2010-04-01 |
| JP2014122231A (ja) | 2014-07-03 |
| CA2715503A1 (en) | 2009-11-12 |
| AU2013205944A1 (en) | 2013-06-06 |
| CN104151428A (zh) | 2014-11-19 |
| EP2250200A2 (en) | 2010-11-17 |
| BRPI0907196B1 (pt) | 2021-05-25 |
| CN104151428B (zh) | 2017-07-14 |
| AU2009244878B2 (en) | 2013-06-13 |
| US20160208004A1 (en) | 2016-07-21 |
| JP2011514335A (ja) | 2011-05-06 |
| US20170114140A1 (en) | 2017-04-27 |
| KR20100115380A (ko) | 2010-10-27 |
| MY184345A (en) | 2021-04-01 |
| US20140322238A1 (en) | 2014-10-30 |
| MX2010009100A (es) | 2010-12-06 |
| WO2009136976A2 (en) | 2009-11-12 |
| CN102037017B (zh) | 2014-07-09 |
| KR101240904B1 (ko) | 2013-03-11 |
| JP5647748B2 (ja) | 2015-01-07 |
| HK1152053A1 (en) | 2012-02-17 |
| CN102037017A (zh) | 2011-04-27 |
| US20110052600A1 (en) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0907196A2 (pt) | Método para inibir ativação do complexo de receptor heteromérico il-17ra-il-17rb | |
| BRPI0916973A2 (pt) | anticorpos para ccr2 | |
| BRPI0917204A2 (pt) | variantes estruturais de anticorpos para melhores características terapêuticas | |
| BRPI0913930A2 (pt) | antagonistas de receptores de prostaglandinas d2 | |
| ES2858225T8 (es) | Procedimiento para producir elementos estructurales templados | |
| PT2231689T (pt) | Novos nucleósidos 7-deazapurina citostáticos | |
| PT2556597T (pt) | Estrutura de pré-codificador para pré-codificação mimo | |
| BRPI0817547A2 (pt) | Método para realizar pirólise | |
| DK2155838T3 (da) | Fremgangsmåde til fremstilling af forgrenede carbonhydrider | |
| UY33094A (es) | Procedimiento para la preparacion de dronedarona | |
| ES2397671T8 (es) | Procedimiento para preparar voriconazol | |
| BRPI0922421A8 (pt) | estrutura de fiação para veículo | |
| DK2511282T3 (da) | Uracylspirooxetannukleosider | |
| BRPI0915032A2 (pt) | hidrogenação de alcanos multi-bromados | |
| EP2445345A4 (en) | benzamide derivatives | |
| BRPI1007459A2 (pt) | método para produção de manômeros olefínicos | |
| DE602008003400D1 (de) | Wabenstruktur | |
| BRPI0819633A2 (pt) | Métodos para produzir poliolefinas | |
| BRPI0816216A2 (pt) | Formulção dispersível em água para liberação de fungos de biocontrole para reduzir aflatoxinas | |
| EP2202211A4 (en) | HONEYCOMB STRUCTURE | |
| BRPI0908466A2 (pt) | construção de embarcação para fpdso | |
| PL2143693T3 (pl) | Struktura plastra miodu | |
| DE602009001201D1 (de) | Wabenstruktur | |
| BRPI0907670A2 (pt) | conjunto de estrutura de aeronave | |
| IT1393062B1 (it) | Procedimento per la preparazione di gemcitabina cloridrato |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: KIRIN-AMGEN INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001 |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/02/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |